In vivo 11β-hydroxysteroid dehydrogenase inhibition in posaconazole-induced hypertension and hypokalemia

George Richard Thompson, Diana Chang, Rebecca R. Wittenberg, Ian Howard Mchardy, Alison Semrad

Research output: Contribution to journalArticle

14 Scopus citations


We describe a case of apparent mineralocorticoid excess (AME) secondary to posaconazole therapy and suggest the biochemical mechanism. Clinical and laboratory investigation confirmed 11β-hydroxysteroid dehydrogenase inhibition and withholding therapy led to a resolution of all clinical and laboratory abnormalities. Posaconazole was later restarted at a lower dose and prevented recurrence of this syndrome. Additional studies are necessary to determine the frequency of posaconazole-induced AME and whether other azole antifungals can be associated with this phenomenon.

Original languageEnglish (US)
Article numbere00760
JournalAntimicrobial Agents and Chemotherapy
Issue number8
StatePublished - Aug 1 2017



  • Antifungal
  • Posaconazole
  • Side effects

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this